Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing

Plain-language summary

This study investigated the effect of Metformin treatment on alternative gene splicing in patients with type 2 diabetes. It enrolled adults with type 2 diabetes who were usually treated with Metformin. It was conducted as a trial with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

Intervention

Metformin

Start date

5/1/2011

Estimated completion

1/1/2012

Countries

France

Related genes

Locations

• Corbeil-Essonnes, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Type 2 Diabetic patients usually treated with metformin (≥ 1400 mg/day), associated or not to other oral anti-diabetic treatment or. injection treatment
* Patients major.
* Patients with a social security number
* Patients having signed a consent to participate in the study

Exclusion Criteria:

* Intolerance metformin
* Patients with type 1.
* Patients on pioglitazone or rosiglitazone
* Renal failure by an anomaly of the creatinine clearance (\< 60 mL/min).
* Patients pregnant or likely to be.